Home > Formulary : Paediatric > Recent Decisions > 2020 >
Tuesday 8th December 2020
Decisions 8th December 2020
At the meeting on the 8th December the following decisions were agreed
New Drug Requests
Approved
Silicone Gel (TLS Amber, no SCP)
- for burns patients who have had treatment initiated by the Scar management clinic (BRCH) and remain under their care and regular review
Shared Care Protocols/TLS changes
New Shared Care Protocol for Digoxin
Other Paediatric Formulary decisions
Following a review of the Endocrine chapter, the following changes have been made:
Demeclocycline changed from TLS Amber to TLS Red
Hydrocortisone (parenteral) changed from TLS Red to TLS Green
Hydrocortisone sodium succinate (solucortef) formulation added as TLS Green
Humalog 100units/ml kwikpen formulation added
Humulin I and Humulin S removed from formulary as not used at BCH for paediatric patients
Humulin R pre-filled pens added as formulation available (TLS Red)
Removal of Insuman products that are discontinued
Novorapid pumpcart for use with insulin pump
Tresiba 100 units/ml- removal of restricted indication for ‘type 1 diabetic patients who have failed on insulin glargine and who are not suitable or failed on insulin pump therapy'
Tresiba 200 units/ml- also an option for insulin resistant Type 1 diabetic patients
Pen needles- BD Viva 4mm needles are preference for the paediatric diabetes team.
BD Autoshield Duo needles are safety pen needle of preference for the paediatric diabetes team.
Glucozade removed
Lanreotide and Octreotide added (TLS Red)
Tostran gel brand added (TLS Amber)
Removal of testosterone capsules (Striant SR) and implants - not used by BCH
Pegvisomant (TLS Red)
Remove Leuprorelin (Prostap) as not used by BCH
Other suggestions and comments were made which may result in future new drug requests or traffic light status changes following submission of paperwork.